<html><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta http-equiv="Content-Style-Type" content="text/css" /><meta name="generator" content="Aspose.Words for .NET 13.4.0.0" /><title>1</title></head><body><div><p style="margin:0pt"><span style="font-family:Calibri; font-size:12pt; font-weight:bold">&#xa0;</span></p><p style="margin:0pt"><span style="font-family:Calibri; font-size:12pt; font-weight:bold">&#xa0;</span></p><p style="margin:0pt"><span style="font-family:Calibri; font-size:12pt; font-weight:bold">&#xa0;</span></p><p style="margin:0pt"><span style="font-family:Calibri; font-size:12pt; font-weight:bold">&#xa0;</span></p><p style="font-size:11pt; line-height:150%; margin:0pt; text-align:center"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Written Evidence submitted by the Advisory Committee on Dangerous Pathogens (BTO0022)</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">1.0</span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">Are UK policies governing who can donate blood and blood products, tissues and organs sufficiently evidence-based? </span><a name="_GoBack"></a><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">Is NHS Blood and Transplant overly restrictive about who can donate, or should greater precautions be taken to further reduce risk?</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">1.1</span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">This question is not being addressed in this submission. </span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">2.0</span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">Is the Government and its scientific advisory structure sufficiently responsive to the threat posed by emerging diseases being transmitted through blood and blood products, tissues and organs?</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">2.1</span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">The Government currently receives advice on a broad range of pathogens with a variety of transmission routes, including through blood, blood products, tissues and organs, from, amongst others, the Advisory Group on Dangerous Pathogens (ACDP).  The ACDP was set up following a smallpox outbreak originating from a laboratory in Birmingham which resulted in the last ever recorded death from the disease.  The official “</span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">Report of the investigation into the cause of the 1978 Birmingham smallpox occurrence</span><span style="font-family:'Times New Roman'; font-size:11pt">” (also known as the Shooter report) recommended the formation of a </span><span style="font-family:'Times New Roman'; font-size:11pt">multidisciplinary</span><span style="font-family:'Times New Roman'; font-size:11pt"> expert group – this became the ACDP.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">2.2</span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">The ACDP advises the Health and Safety Executive (HSE), Ministers for the Department of Health (DH) and the Department for the Environment, Food &amp; Rural Affairs (DEFRA), and their counterparts in the devolved administrations, as required, on all aspects of hazards and risks to workers and others from exposure to pathogens (Appendix A - ACDP Membership, Terms of Reference and work plan for 2013/14).  </span><span style="font-family:'Times New Roman'; font-size:11pt">The Committee comprises a Chairman and approximately fifteen members.   Its remit has evolved over time and recently the ACDP has absorbed the work of other groups dealing with infections, notably </span><span style="font-family:'Times New Roman'; font-size:11pt">the Spongiform Encephalopathy Advisory Committee (SEAC).</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt 0pt 12pt; text-align:justify"><span style="color:#111111; font-family:'Times New Roman'; font-size:11pt">2.3</span><span style="color:#111111; font-family:'Times New Roman'; font-size:11pt">              </span><span style="color:#111111; font-family:'Times New Roman'; font-size:11pt">Over the past 20 years there have been a variety of committees providing expert advice to the Government on </span><span style="color:#111111; font-family:'Times New Roman'; font-size:11pt; font-weight:normal">Creutzfeldt-Jakob disease (CJD) and other </span><span style="color:#111111; font-family:'Times New Roman'; font-size:11pt">Transmissible Spongiform Encephalopathies (</span><span style="color:#111111; font-family:'Times New Roman'; font-size:11pt; font-weight:normal">TSEs) and the risk they pose to health.  </span><span style="color:#111111; font-family:'Times New Roman'; font-size:11pt">In April 1990 the Spongiform Encephalopathy Advisory Committee (SEAC) was formed to provide independent expert scientific advice to the Government on TSEs such as BSE, CJD and scrapie.  SEAC's remit was wide-ranging, and covered public health, food safety and animal health issues.  Following its abolition in March 2011 its responsibilities passed to the ACDP.  </span></p><p style="margin:0pt 0pt 12pt; text-align:justify"><span style="color:#111111; font-family:'Times New Roman'; font-size:11pt">2.4 </span><span style="color:#111111; font-family:'Times New Roman'; font-size:11pt">              </span><span style="color:#111111; font-family:'Times New Roman'; font-size:11pt">In order to handle these new responsibilities, which require specialist expertise, ACDP created the ACDP TSE Risk Management and the ACDP TSE Risk Assessment Sub Groups.  These merged in November 2013 to form a single ACDP TSE Sub Group (Appendix B - ACDP TSE SG Membership, Terms of Reference and work plan for 2013/14).  The ACDP TSE SG advises specifically on risk assessment and risk management of CJD and other TSEs.  A raft of infection control guidance has been produced by the ACDP TSE SG in order to minimise CJD transmission between patients.  This covers precautions that should be taken if it is known that a patient has, or is at increased risk of, CJD and is undergoing surgery on infectious tissues. It also gives recommendations on decontamination procedures in line with other national guidance (Appendix C – ACDP TSE SG infection prevention and control guidance).</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">2.5</span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">In 2000, the UK Chief Medical Officers set up the CJD Incidents Panel (CJD IP), an independent expert advisory committee, to advise hospitals, Trusts and public health teams across the UK about the management of incidents involving all types of CJD that might result in person to person transmission.  This panel included experts in prion diseases, senior level representatives from a variety of relevant clinical specialties as well as decontamination specialists, lawyers, medical ethicists and representatives of patient groups.  It provided a unique forum for the discussion and </span><span style="font-family:'Times New Roman'; font-size:11pt">management of CJD incidents within the NHS and usefully informed risk management.  The CJD IP was wound up in March 2013 but has left a strong legacy of decisions that form practical precedents for any new incidents and a document of framework advice.   This work has been incorporated into a national guidance document for the management of CJD incidents (Appendix D – CJD incident management guidance).  In addition, the Panel produced an Organs and Tissue Position Statement (Appendix E).  The management of individual incidents of healthcare exposure to CJD is now devolved to hospitals, Trusts and public health teams.  More general advice and guidance now lies with the ACDP’s TSE Sub-Group.  In addition, support is available from the CJD Section of the National Centre for Infectious Disease Surveillance and Control of Public Health England.  This acts as a clearing house for queries and can link enquirers with the UK’s various specialist clinical and research teams such as the National CJD Research and Surveillance Unit, at Edinburgh University, the Medical Research Council Prion Unit/NHS National Prion Clinic at University College London and Great Ormond Street Children’s Hospital.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic"> </span><span style="font-family:'Times New Roman'; font-size:11pt">2.6</span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">The joint Human Animal Infections and Risk Surveillance (HAIRS) group also reports into ACDP.  The HAIRS group is a multi-agency and cross-disciplinary horizon scanning group set up to examine risks across the all  infectious diseases, not specifically spongiform encephalopathies, which are largely dealt with by ACDP.  The HAIRS group meets to identify and discuss infections with potential for interspecies transfer (particularly zoonotic infections) which may pose a threat to UK public health (Appendix F – HAIRS Membership and Terms of Reference; </span><a href="http://www.hpa.org.uk/Topics/InfectiousDiseases/InfectionsAZ/EmergingInfections/HAIRS/"><span style="color:#0000ff; font-family:'Times New Roman'; font-size:11pt; text-decoration:underline">http://www.hpa.org.uk/Topics/InfectiousDiseases/InfectionsAZ/EmergingInfections/HAIRS/</span></a><span style="font-family:'Times New Roman'; font-size:11pt">). Inasmuch as HAIRS identifies risks associated with the blood supply, those risks rather than being dealt with at ACDP, are largely addressed by groups that address the safety of the blood supply such as Advisory Committee on the Safety of Blood, Tissues and Organs (SaBTO) and the UK blood services Prion Working Group (PWG).</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">2.7</span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">These committees all have a culture of working in a timely way to advise governments on the threats posed by emerging infectious diseases, including spongiform encephalopathies, although it has to be acknowledged that scientific uncertainties, a particular difficulty in prion infections for which much of the science is very different from more conventional infections, may inevitably delay what turns out, with hindsight, to be the correct response.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">3.0</span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">Has the threat of ongoing transmission of vCJD through the blood and blood product supply been adequately mitigated?</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">3.1</span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">The ACDP and its TSE SG was consulted several times during the development of the Department of Health’s paper “</span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">vCJD and transfusion of blood components: An updated risk assessment</span><span style="font-family:'Times New Roman'; font-size:11pt">” (Appendix G).  </span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">3.2</span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">Following the publication of the risk assessment in April 2012, the ACDP published its “</span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">Position Statement on occurrence of vCJD and prevalence of infection in the UK population</span><span style="font-family:'Times New Roman'; font-size:11pt">” July 2012 (Appendix H).  The aim of this document was to make available a summary of current thinking on some key scientific issues relating to vCJD including secondary transmission, including what is not known.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">3.3</span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">This document considers the risks of secondary (person-to-person) transmission in some detail, including through blood and blood products.  The approach set out is a precautionary one that continues to be applied in the preparation of the ACDP TSE infection control guidance that is attached to this submission (Appendix C).</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">3.4</span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">Several different groups of patients have been identified as being at increased risk of iatrogenic CJD and vCJD due to medical treatment they have received in the past.  Most of these groups have been notified so their healthcare providers can take the necessary precautions to prevent </span><span style="font-family:'Times New Roman'; font-size:11pt">possible secondary transmission through surgery or other invasive treatments.  These precautions are detailed in the ACDP TSE SG infection control guidance (Appendix C).  Individuals notified as being at increased risk are also told not to donate blood, organs and tissues.  </span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">3.5</span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">There are, however, certain individuals who, despite being at increased risk of vCJD, have not been notified.  For example, individuals at increased risk due to having received large volumes of blood in the course of their medical treatment have not been notified. This group has been discussed at length by ACDP TSE SG, and a majority recommendation not to identify and inform these patients was made, not least because the organisation of health records is such that there is no straightforward way of identifying many of them and their level of risk is difficult to calculate with any degree of certainty.  However, this was not a unanimous decision, and the ACDP TSE SG will keep the issue under review. Although these people may be unaware of their risk status they will not be endangering the blood and blood products supply as anyone who has received donated blood themselves is not allowed to donate blood.  The decision made by the UK blood services to stop recipients of blood and blood products from donating blood was a hugely significant step in reducing the risk of ongoing transmission of vCJD through blood and blood products.  However, there is, in theory at least, some risk from these patients relating to surgery on infectious tissues and the ACDP TSE SG continues to look for practical and equitable ways of managing this risk.     </span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">3.6</span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">In its position statement (Appendix H), the ACDP emphasises that fundamental research into prion diseases needs to continue as well as consistent, long-term surveillance of the UK population.  It also stated that, despite the fact that vCJD remains rare and deaths from the disease peaked in the UK in the year 2000, the indication from the recent study commissioned by DH (Health Protection Report </span><span style="font-family:'Times New Roman'; font-size:11pt">Volume </span><span style="font-family:'Times New Roman'; font-size:11pt">6</span><span style="font-family:'Times New Roman'; font-size:11pt"> No </span><span style="font-family:'Times New Roman'; font-size:11pt">32</span><span style="font-family:'Times New Roman'; font-size:11pt">; 10 August 2012; </span><span style="font-family:'Times New Roman'; font-size:11pt">Gill ON </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">et al</span><span style="font-family:'Times New Roman'; font-size:11pt">. Prevalent abnormal prion protein in human appendices after bovine spongiform encephalopathy epizootic: large scale survey. </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">BMJ </span><span style="font-family:'Times New Roman'; font-size:11pt">2013;347:f5675) that prion protein deposition occurs in the appendices of about 1 in 2,000 of the UK population necessitated continued attention to the risks of secondary, person-to-person transmission, including through blood and blood products.  The Committee recommended that this should include research to support the development and implementation of risk management strategies and the gaining of further information on prevalence of infection in tissues and blood.  This approach, of course, equates abnormal prion protein deposition in the appendix with prion infectivity in other tissues, including blood.  This would imply that the person from whom that appendix was removed is infectious to others. This may or may not be true and there is a range of opinion within ACDP and the ACDP TSE Sub Group concerning the significance of the findings in the appendix studies for estimating the prevalence of vCJD infection in the UK.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">3.7 </span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">Certainly infection has been transmitted to laboratory mice from the prion protein found in the spleen of an individual who died from other causes but had previously received blood from someone who later died of vCJD: see</span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic; font-weight:bold"> </span><span style="font-family:'Times New Roman'; font-size:11pt">Bishop MT, Diack AB, Ritchie DL </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">et al</span><span style="font-family:'Times New Roman'; font-size:11pt">.  </span><span style="font-family:'Times New Roman'; font-size:11pt">Prion infectivity in the spleen of a PRNP heterozygous individual with subclinical variant Creutzfeldt–Jakob disease. </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">Brain </span><span style="font-family:'Times New Roman'; font-size:11pt">2013 Apr;</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">136; </span><span style="font-family:'Times New Roman'; font-size:11pt">(Pt 4):</span><span style="font-family:'Times New Roman'; font-size:11pt">1139–1145</span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic"> </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">doi: 10.1093/brain/awt032. Epub </span><span style="font-family:'Times New Roman'; font-size:11pt">2013 Feb 28</span><span style="font-family:'Times New Roman'; font-size:11pt">. There is also transmission data in a number of animal species indicating a correlation between abnormal prion protein deposition in lymphoreticular tissue (</span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">ie </span><span style="font-family:'Times New Roman'; font-size:11pt">tissue like that found in the appendix</span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">)</span><span style="font-family:'Times New Roman'; font-size:11pt"> and prion infectivity.  Such lymphoreticular tissues have also been shown to be positive for abnormal PrP prior to symptom onset in vCJD (Hilton </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">et al</span><span style="font-family:'Times New Roman'; font-size:11pt">.</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal"> </span><span style="font-family:'Times New Roman'; font-size:11pt">Prion immunoreactivity in appendix before clinical onset of variant Creutzfeldt-Jakob disease</span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">. </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">Lancet</span><span style="font-family:'Times New Roman'; font-size:11pt"> 1998</span><span style="font-family:'Times New Roman'; font-size:11pt">; 352:703-704.</span><span style="font-family:'Times New Roman'; font-size:11pt">).  However, others question whether prion protein deposition in the appendix is, in fact, some sort of non-specific phenomenon, unrelated to dietary exposure to BSE. They also question whether, if the estimated prevalence of infection from the appendix studies is indeed 1 in 2000 and some 2 million blood donations occur a year, more vCJD cases would have been expected to have occurred. </span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">3.8</span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">Ultimately these differing judgements can only be resolved by further research.  Assuming an appropriately performing blood test was available (see paragraphs 3.9 - 3.10 below) a blood </span><span style="font-family:'Times New Roman'; font-size:11pt">prevalence study could be carried out, and sufficient of the blood sample retained to check whether infectivity could be established in appropriate laboratory animals from the “positive” blood samples.  In any case, examination of appendices taken out in the UK before 1980 (the rough start date </span><span style="font-family:'Times New Roman'; font-size:11pt">for the BSE epidemic</span><span style="font-family:'Times New Roman'; font-size:11pt"> in the UK) and after 1996 (when it was substantially eliminated from the food chain) is under way to provide information on the extent to which prion protein deposition in the appendix is, in fact, related to BSE exposure.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">3.9</span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt"> The Committee supports the development of an accurate and effective blood test to facilitate the task of taking proportionate preventive action.  </span><span style="font-family:'Times New Roman'; font-size:11pt">To further this aim, in October 2012 the ACDP hosted a meeting together with another</span><span style="font-family:'Times New Roman'; font-size:11pt"> expert group, the </span><span style="font-family:'Times New Roman'; font-size:11pt">UK Blood Services  Prion Working Group, </span><span style="font-family:'Times New Roman'; font-size:11pt">where a series of presentations from</span><span style="font-family:'Times New Roman'; font-size:11pt"> four different research groups involved in the development of</span><span style="font-family:'Times New Roman'; font-size:11pt"> vCJD blood tests were given. </span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">3.10</span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">This meeting highlighted the difficulties faced by researchers working in this area and the limitations of the blood tests available at this time.  This was in terms of their reliability/ sensitivity and the suitability of the assays for large scale screening, taking account of the minimum requirements for both sensitivity and specificity as set out in the European </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">In Vitro </span><span style="font-family:'Times New Roman'; font-size:11pt">Diagnostic Directive.  The ACDP, nevertheless, is committed to continuing its support of this research and welcomes the opportunity to work alongside other expert committees involved in this area of work.  For example, an Oversight Committee was established in 2007 to monitor and direct the work of the </span><span style="font-family:'Times New Roman'; font-size:11pt">National Institute for Biological Standards and Control (NIBSC) </span><span style="font-family:'Times New Roman'; font-size:11pt">based CJD Resource Centre.  This facilitates the development of blood tests through the provision of samples and blind panels for assessment by those developing such tests.  It is important to recognise that the performance characteristics of a test that might be used to identify potentially infectious blood donors might well be different from those that would be suitable for a population prevalence survey.  </span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">3.11</span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">In conclusion, we cannot be sure that the number of vCJD cases currently identified represents the end of this disease in the UK.  The results of the recent study by Gill </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">et al.</span><span style="font-family:'Times New Roman'; font-size:11pt"> (paragraph 3.6, above) indicate that the possibility of an unknown number of further future cases cannot be excluded, especially in view of the lengthy disease incubation period of these diseases which may reach several decades, and other scientific uncertainties that still surround the behaviour of the prion agents. Examples of these uncertainties are the full scope of the natural history, symptoms and pathological pattern of disease, as well as the influence of genetic variations in susceptibility to these diseases in the UK population.  Therefore, BSE and vCJD will continue to be of concern to health professionals and the public for the foreseeable future.  </span></p><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">4.0</span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">What are the strengths and weaknesses of NHS Blood and Transplant’s strategy, “Taking Organ Transplantation to 2020”? What further changes could be made to safely increase the supply of blood and blood products, tissues and organs?</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">4.1</span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">This question is not being addressed in this submission.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">5.0</span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">What lessons could be learnt from the screening and donation practices of other countries?</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">5.1</span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">This question is not being addressed in this submission.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">January 2014</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">List of Appendices and links:</span></p><p style="margin:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt 0pt 6pt"><span style="font-family:'Times New Roman'; font-size:11pt">Appendix A - ACDP Membership, Terms of Reference and work plan for 2013/14 (attached)</span></p><p style="margin:0pt 0pt 6pt"><span style="font-family:'Times New Roman'; font-size:11pt">Appendix B - ACDP TSE SG Membership, Terms of Reference and work plan for 2013/14 (attached)</span></p><p style="margin:0pt 0pt 6pt"><span style="font-family:'Times New Roman'; font-size:11pt">Appendix C - ACDP TSE SG infection control guidance</span></p><p style="margin:0pt 0pt 6pt 54pt; text-indent:-36pt"><span style="font-family:'Times New Roman'; font-size:11pt">i)</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt">Part 1 – Introduction </span><a href="https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/209755/Part_1_-_Introduction.pdf"><span style="color:#0000ff; font-family:'Times New Roman'; font-size:11pt; text-decoration:underline">https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/209755/Part_1_-_Introduction.pdf</span></a><span style="font-family:'Times New Roman'; font-size:11pt"> </span></p><p style="margin:0pt 0pt 6pt 54pt; text-indent:-36pt"><span style="font-family:'Times New Roman'; font-size:11pt">ii)</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt">Part 2 – Health and Safety Management of transmissible spongiform encephalopathy </span><a href="https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/209756/Part_2_-_Health_and_Safety.pdf"><span style="color:#0000ff; font-family:'Times New Roman'; font-size:11pt; text-decoration:underline">https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/209756/Part_2_-_Health_and_Safety.pdf</span></a></p><p style="margin:0pt 0pt 6pt 54pt; text-indent:-36pt"><span style="font-family:'Times New Roman'; font-size:11pt">iii)</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt">Part 3 – Laboratory Containment and control measures </span><a href="https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/209757/Part_3_-_Laboratory_containment_and_control_measures.pdf"><span style="color:#0000ff; font-family:'Times New Roman'; font-size:11pt; text-decoration:underline">https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/209757/Part_3_-_Laboratory_containment_and_control_measures.pdf</span></a></p><p style="margin:0pt 0pt 6pt 54pt; text-indent:-36pt"><span style="font-family:'Times New Roman'; font-size:11pt">iv)</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt">Part 4 – Infection Control of CJD, vCJD and other human prion diseases in healthcare and community settings </span><a href="https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/270732/Part_4_Infection_control_of_CJD__vCJD_and_other_human_prion_diseases_in_healthcare_and_community_settings.pdf"><span style="color:#0000ff; font-family:'Times New Roman'; font-size:11pt; text-decoration:underline">https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/270732/Part_4_Infection_control_of_CJD__vCJD_and_other_human_prion_diseases_in_healthcare_and_community_settings.pdf</span></a></p><p style="margin:0pt 0pt 6pt 54pt; text-indent:-36pt"><span style="font-family:'Times New Roman'; font-size:11pt">v)</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt">Annex A1: Distribution of transmissible spongiform encephalopathy infectivity in human tissues and body fluids </span><a href="https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/209759/Annex_A1_-_Distribution_of_TSE_infectivity.pdf"><span style="color:#0000ff; font-family:'Times New Roman'; font-size:11pt; text-decoration:underline">https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/209759/Annex_A1_-_Distribution_of_TSE_infectivity.pdf</span></a></p><p style="margin:0pt 0pt 6pt 54pt; text-indent:-36pt"><span style="font-family:'Times New Roman'; font-size:11pt">vi)</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt">Annex A2: Distribution of infectivity in animal tissue and body fluids </span><a href="https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/209760/Annex_A2_-_Distribution_of_infectivity_in_animal_tissue.pdf"><span style="color:#0000ff; font-family:'Times New Roman'; font-size:11pt; text-decoration:underline">https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/209760/Annex_A2_-_Distribution_of_infectivity_in_animal_tissue.pdf</span></a></p><p style="margin:0pt 0pt 6pt 54pt; text-indent:-36pt"><span style="font-family:'Times New Roman'; font-size:11pt">vii)</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt">Annex B: Diagnostic criteria </span><a href="https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/209761/Annex_B_-_Diagnostic_criteria.pdf"><span style="color:#0000ff; font-family:'Times New Roman'; font-size:11pt; text-decoration:underline">https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/209761/Annex_B_-_Diagnostic_criteria.pdf</span></a></p><p style="margin:0pt 0pt 6pt 54pt; text-indent:-36pt"><span style="font-family:'Times New Roman'; font-size:11pt">viii)</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt">Annex C: General principles of decontamination and waste disposal </span><a href="https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/209762/Annex_C_-_General_principles_of_decontamination.pdf"><span style="color:#0000ff; font-family:'Times New Roman'; font-size:11pt; text-decoration:underline">https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/209762/Annex_C_-_General_principles_of_decontamination.pdf</span></a></p><p style="margin:0pt 0pt 6pt 54pt; text-indent:-36pt"><span style="font-family:'Times New Roman'; font-size:11pt">ix)</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt">Annex D: Transport of transmissible spongiform encephalopathy-infected material </span><a href="https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/209763/Annex_D_-_Transport_of_TSE-infected_material.pdf"><span style="color:#0000ff; font-family:'Times New Roman'; font-size:11pt; text-decoration:underline">https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/209763/Annex_D_-_Transport_of_TSE-infected_material.pdf</span></a></p><p style="margin:0pt 0pt 6pt 54pt; text-indent:-36pt"><span style="font-family:'Times New Roman'; font-size:11pt">x)</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt">Annex E: Quarantining of surgical instruments </span><a href="https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/209764/Annex_E_-_Quarantining_of_surgical_instruments.pdf"><span style="color:#0000ff; font-family:'Times New Roman'; font-size:11pt; text-decoration:underline">https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/209764/Annex_E_-_Quarantining_of_surgical_instruments.pdf</span></a></p><p style="margin:0pt 0pt 6pt 54pt; text-indent:-36pt"><span style="font-family:'Times New Roman'; font-size:11pt">xi)</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt">Annex F: Endoscopy (note there is no Annex G at present) </span><a href="https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/270734/Annex_F_Endoscopy.pdf"><span style="color:#0000ff; font-family:'Times New Roman'; font-size:11pt; text-decoration:underline">https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/270734/Annex_F_Endoscopy.pdf</span></a></p><p style="margin:0pt 0pt 6pt 54pt; text-indent:-36pt"><span style="font-family:'Times New Roman'; font-size:11pt">xii)</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt">Annex H: After death </span><a href="https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/209766/Annex_H_-_After_death.pdf"><span style="color:#0000ff; font-family:'Times New Roman'; font-size:11pt; text-decoration:underline">https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/209766/Annex_H_-_After_death.pdf</span></a></p><p style="margin:0pt 0pt 6pt 54pt; text-indent:-36pt"><span style="font-family:'Times New Roman'; font-size:11pt">xiii)</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt">Annex I: Outline protocol for management of instruments and tissues from brain biopsy procedures on patients with progressive neurological disorders </span><a href="https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/209767/Annex_I_-_Outline_protocol_for_managment_of_instruments_and_tissues.pdf"><span style="color:#0000ff; font-family:'Times New Roman'; font-size:11pt; text-decoration:underline">https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/209767/Annex_I_-_Outline_protocol_for_managment_of_instruments_and_tissues.pdf</span></a></p><p style="margin:0pt 0pt 6pt 54pt; text-indent:-36pt"><span style="font-family:'Times New Roman'; font-size:11pt">xiv)</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt">Annex J: Assessment to be carried out before surgery and or endoscopy to identify patients with, or at risk of, CJD or vCJD </span><a href="https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/270735/Annex_J_Assessment_to_be_carried_out_before_surgery_and_or_endoscopy_to_identify_patients_with__or_at_risk_of__CJD_or_vCJD.pdf"><span style="color:#0000ff; font-family:'Times New Roman'; font-size:11pt; text-decoration:underline">https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/270735/Annex_J_Assessment_to_be_carried_out_before_surgery_and_or_endoscopy_to_identify_patients_with__or_at_risk_of__CJD_or_vCJD.pdf</span></a></p><p style="margin:0pt 0pt 6pt 54pt; text-indent:-36pt"><span style="font-family:'Times New Roman'; font-size:11pt">xv)</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt">Annex K: Guidelines for pathologists and pathology laboratories for the handling of tissues from patients with, or at risk of, CJD or vCJD </span><a href="https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/209769/Annex_K_-_Guidelines_for_pathologist_and_pathology_laboratories.pdf"><span style="color:#0000ff; font-family:'Times New Roman'; font-size:11pt; text-decoration:underline">https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/209769/Annex_K_-_Guidelines_for_pathologist_and_pathology_laboratories.pdf</span></a></p><p style="margin:0pt 0pt 6pt 54pt; text-indent:-36pt"><span style="font-family:'Times New Roman'; font-size:11pt">xvi)</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt">Annex L: Managing CJD vCJD risk in ophthalmology </span><a href="https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/209770/Annex_L_-_Managing_CJD_vCJD_risk_in_ophthalmology.pdf"><span style="color:#0000ff; font-family:'Times New Roman'; font-size:11pt; text-decoration:underline">https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/209770/Annex_L_-_Managing_CJD_vCJD_risk_in_ophthalmology.pdf</span></a></p><p style="margin:0pt 0pt 6pt 54pt; text-indent:-36pt"><span style="font-family:'Times New Roman'; font-size:11pt">xvii)</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt">Annex M: Managing vCJD risk in general surgery and liver transplantation </span><a href="https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/209780/Annex_M_-_Mananging_vCJD_risk.pdf"><span style="color:#0000ff; font-family:'Times New Roman'; font-size:11pt; text-decoration:underline">https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/209780/Annex_M_-_Mananging_vCJD_risk.pdf</span></a></p><p style="margin:0pt 0pt 6pt 54pt; text-indent:-36pt"><span style="font-family:'Times New Roman'; font-size:11pt">xviii)</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt">CJD guidance for opthalmologists </span><a href="https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/209772/CJD_guidance_for_ophthalmologists.pdf"><span style="color:#0000ff; font-family:'Times New Roman'; font-size:11pt; text-decoration:underline">https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/209772/CJD_guidance_for_ophthalmologists.pdf</span></a></p><p style="margin:0pt 0pt 6pt 54pt; text-indent:-36pt"><span style="font-family:'Times New Roman'; font-size:11pt">xix)</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt">Information sheet for funeral directors, relatives and others following a CJD death </span><a href="https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/209773/Information_sheet_for_funeral_directors__relatives_and_others_following_a_CJD_death.pdf"><span style="color:#0000ff; font-family:'Times New Roman'; font-size:11pt; text-decoration:underline">https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/209773/Information_sheet_for_funeral_directors__relatives_and_others_following_a_CJD_death.pdf</span></a></p><p style="margin:0pt 0pt 6pt 54pt; text-indent:-36pt"><span style="font-family:'Times New Roman'; font-size:11pt">xx)</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt">Alert to urological surgeons regarding the equipment used for patients at risk of vCJD requiring transrectal prostatic biopsy </span><a href="https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/209781/Alert_to_urological_surgeons.pdf"><span style="color:#0000ff; font-family:'Times New Roman'; font-size:11pt; text-decoration:underline">https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/209781/Alert_to_urological_surgeons.pdf</span></a></p><p style="margin:0pt 0pt 6pt 54pt; text-indent:-36pt"><span style="font-family:'Times New Roman'; font-size:11pt">xxi)</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt">Frequently asked questions </span><a href="https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/209775/Frequently_Asked_Questions.pdf"><span style="color:#0000ff; font-family:'Times New Roman'; font-size:11pt; text-decoration:underline">https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/209775/Frequently_Asked_Questions.pdf</span></a></p><p style="margin:0pt 0pt 6pt 54pt; text-indent:-36pt"><span style="font-family:'Times New Roman'; font-size:11pt">xxii)</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt">Abbreviations </span><a href="https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/209776/Abbreviations.pdf"><span style="color:#0000ff; font-family:'Times New Roman'; font-size:11pt; text-decoration:underline">https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/209776/Abbreviations.pdf</span></a></p><p style="margin:0pt 0pt 6pt"><span style="font-family:'Times New Roman'; font-size:11pt">Appendix D - CJD incident management guidance </span><a href="http://www.hpa.org.uk/Topics/InfectiousDiseases/InfectionsAZ/CreutzfeldtJakobDisease/CJDGuidanceAndAdvice/"><span style="color:#0000ff; font-family:'Times New Roman'; font-size:11pt; text-decoration:underline">http://www.hpa.org.uk/Topics/InfectiousDiseases/InfectionsAZ/CreutzfeldtJakobDisease/CJDGuidanceAndAdvice/</span></a></p><p style="margin:0pt 0pt 6pt"><span style="font-family:'Times New Roman'; font-size:11pt">Appendix E - CJD IP Organs and Tissue Position Statement (attached)</span></p><p style="margin:0pt 0pt 6pt"><span style="font-family:'Times New Roman'; font-size:11pt">Appendix F - HAIRS Terms of Reference and Membership (attached)</span></p><p style="margin:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Appendix G - Department of Health’s paper “</span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">vCJD and transfusion of blood components: An updated risk assessment</span><span style="font-family:'Times New Roman'; font-size:11pt">”</span></p><p style="margin:0pt 0pt 6pt"><a href="https://www.gov.uk/government/publications/vcjd-and-transfusion-of-blood-components-updated-risk-assessment"><span style="color:#0000ff; font-family:'Times New Roman'; font-size:11pt; text-decoration:underline">https://www.gov.uk/government/publications/vcjd-and-transfusion-of-blood-components-updated-risk-assessment</span></a></p><p style="margin:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Appendix H - ACDP “</span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">Position Statement on occurrence of vCJD and prevalence of infection in the UK population</span><span style="font-family:'Times New Roman'; font-size:11pt">” July 2012</span></p><p style="margin:0pt 0pt 6pt"><a href="http://media.dh.gov.uk/network/261/files/2012/08/ACDP-statement-vCJD-occurrence-and-prevalence-Jul-2012.pdf"><span style="color:#0000ff; font-family:'Times New Roman'; font-size:11pt; text-decoration:underline">http://media.dh.gov.uk/network/261/files/2012/08/ACDP-statement-vCJD-occurrence-and-prevalence-Jul-2012.pdf</span></a></p><p style="margin:0pt 0pt 6pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><br style="page-break-before:always; clear:both" /><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Appendix A - ACDP Membership, Terms of Reference and work plan for 2013/14</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><table cellspacing="0" cellpadding="0" style="border-collapse:collapse; margin-left:0pt; width:453.65pt"><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:120.55pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Independent Member</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:333.1pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Area of expertise</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:120.55pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Prof George Griffin (Chair)</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:333.1pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Clinical and research microbiology and infectious diseases</span></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:120.55pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Dr Roland Salmon</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:333.1pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Epidemiology/ public health </span></p></td></tr><tr style="height:3.5pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:120.55pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Prof Richard Tedder</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:333.1pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Clinical virology</span></p></td></tr><tr style="height:3.5pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:120.55pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Prof Malcolm Bennett</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:333.1pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Environmental/veterinary microbiology</span></p></td></tr><tr style="height:3.5pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:120.55pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Prof Armine Sefton </span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:333.1pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Clinical or research bacteriology</span></p></td></tr><tr style="height:3.5pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:120.55pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Prof Dominic Mellor</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:333.1pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Veterinary surgeon specialising in veterinary microbiology, epidemiology and/or population medicine</span></p></td></tr><tr style="height:3.5pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:120.55pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Dr Judith Hilton</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:333.1pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Risk assessment and management</span></p></td></tr><tr style="height:3.5pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:120.55pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Prof Richard Knight</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:333.1pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Pathologist/clinical neurologist</span></p></td></tr><tr style="height:3.5pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:120.55pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Prof Jean Manson</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:333.1pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Prion science and prion disease</span></p></td></tr><tr style="height:3.5pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:120.55pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Dr Malcolm Holliday</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:333.1pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Biomedical Scientist with experience of working at high containment levels</span></p></td></tr><tr style="height:3.5pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:120.55pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Dr Anne Tunbridge</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:333.1pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Infectious diseases specialist</span></p></td></tr><tr style="height:3.5pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:120.55pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Dr Robert Shorten</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:333.1pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Biomedical Scientist with experience of working at high containment levels</span></p></td></tr><tr style="height:3.5pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:120.55pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Dr / Lt Col Tiffany Hemming</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:333.1pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Epidemiologist/veterinarian</span></p></td></tr><tr style="height:3.5pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:120.55pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Prof Peter Chiodini</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:333.1pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Parasitologist/Infectious diseases specialist</span></p></td></tr><tr style="height:3.5pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:120.55pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Dr Michael Kidd</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:333.1pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Clinical Virologist specialising in respiratory viruses</span></p></td></tr><tr style="height:3.5pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:120.55pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Dr Michael Jacobs</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:333.1pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Infectious Diseases specialist</span></p></td></tr></table><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Advisory Committee on Dangerous Pathogens Terms of Reference </span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">“To provide as requested independent scientific advice to the Health and Safety Executive, and to Ministers through the Department of Health, the Department for Environment, Food and Rural Affairs, and their counterparts under devolution in Scotland, Wales and Northern Ireland, on all aspects of hazards and risks to workers and others from exposure to pathogens. In addition, to provide as requested independent scientific risk assessment advice on transmissible spongiform encephalopathies (TSEs) to Ministers through the Department of Health, the Department for Environment, Food and Rural Affairs, and their counterparts under devolution in Scotland, Wales and Northern Ireland and to the Food Standards Agency.”</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Advisory Committee on Dangerous Pathogens Work Plan for 2013/2014</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; list-style-position:inside; margin:0pt; text-align:justify; text-indent:0pt"><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt">To maintain oversight of the work plan of the ACDP TSE Risk Assessment and TSE Risk Management Sub Groups</span></li><li style="font-family:'Times New Roman'; font-size:11pt; list-style-position:inside; margin:0pt; text-align:justify; text-indent:0pt"><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt">To review and update existing ACDP published guidance according to agreed priorities</span></li><li style="font-family:'Times New Roman'; font-size:11pt; list-style-position:inside; margin:0pt; text-align:justify; text-indent:0pt"><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt">To produce an annual report</span></li></ol><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><br style="page-break-before:always; clear:both" /></p><p style="margin:0pt 0pt 6pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Appendix B - ACDP TSE SG Membership, Terms of Reference and work plan for 2013/14</span></p><table cellspacing="0" cellpadding="0" style="border-collapse:collapse; margin-left:0pt; width:453.65pt"><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:120.55pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Independent Member</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:333.1pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Area of expertise</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:120.55pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Prof George Griffin (Joint Chair)</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:333.1pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Clinical and research microbiology and infectious diseases</span></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:120.55pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Dr Roland Salmon (Joint Chair)</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:333.1pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Epidemiology/ public health </span></p></td></tr><tr style="height:3.5pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:120.55pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Prof Malcolm Bennett</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:333.1pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Environmental/veterinary microbiology</span></p></td></tr><tr style="height:3.5pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:120.55pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Prof Richard Knight</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:333.1pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Pathologist/clinical neurologist</span></p></td></tr><tr style="height:3.5pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:120.55pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Prof Jean Manson</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:333.1pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Prion science and prion disease</span></p></td></tr><tr style="height:3.5pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:120.55pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Stella Barnass</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:333.1pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p></td></tr><tr style="height:3.5pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:120.55pt"><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">Patricia Hewitt</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:333.1pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p></td></tr><tr style="height:3.5pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:120.55pt"><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">James Ironside</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:333.1pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Prion science and prion disease</span></p></td></tr><tr style="height:3.5pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:120.55pt"><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">Simon Mead</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:333.1pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Prion science and prion disease</span></p></td></tr><tr style="height:3.5pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:120.55pt"><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">Graham Medley</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:333.1pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p></td></tr><tr style="height:3.5pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:120.55pt"><p style="margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">Geoff Ridgway</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:333.1pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Medical Microbiologist (retired)</span></p></td></tr><tr style="height:3.5pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:120.55pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">Gerry Bryant</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:333.1pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p></td></tr><tr style="height:3.5pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:120.55pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">Phil Minor</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:333.1pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p></td></tr><tr style="height:3.5pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:120.55pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">Colin Howard</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:333.1pt"><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p></td></tr></table><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Advisory Committee on Dangerous Pathogens TSE Sub Group Terms of Reference </span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">“To provide ACDP as requested with practical, scientifically based advice on the assessment and the management of risks from transmissible spongiform encephalopathies (TSEs).  This advice should be in relation to food safety, public and animal health issues, taking appropriate account of present scientific uncertainty and assumptions in formulating advice on risk.  To handle issues as referred, taking into account the work of other relevant bodies."</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Advisory Committee on Dangerous Pathogens TSE Sub Group Work Plan for 2013/2014</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 13.1pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">To review, revise and update the current range of TSE guidance* in collaboration with stakeholders</span></li><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 13.1pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">To review Annex G of the TSE guidance* on specialist equipment in collaboration with stakeholders</span></li><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 13.1pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="color:#111111; font-family:'Times New Roman'; font-size:11pt">To publish an additional Annex to the TSE guidance* to provide comprehensive and up-to-date advice on surgical procedures involving medium risk tissue</span></li><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 13.1pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">To review and update as necessary Annex J in collaboration with the Society of British Neurological Surgeons</span></li><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 13.1pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Provide advice, if needed, on new issues arising from local patient notifications of increased CJD risk.</span></li></ol><p style="margin:0pt 0pt 0pt 17.85pt; text-align:justify; text-indent:-17.85pt"><span style="font-family:'Times New Roman'; font-size:11pt">6. </span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">To review evidence of transmission of vCJD via surgery</span></p><p style="margin:0pt 0pt 0pt 17.85pt; text-align:justify; text-indent:-17.85pt"><span style="font-family:'Times New Roman'; font-size:11pt">7. </span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">To review scenarios and epidemiology associated with TSE prevalence studies</span></p><p style="margin:0pt 0pt 0pt 17.85pt; text-align:justify; text-indent:-17.85pt"><span style="font-family:'Times New Roman'; font-size:11pt">8.</span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">To review, in conjunction with the UK Blood Services Prion Working Group, the development of prototype blood tests for abnormal prion protein</span></p><p style="margin:0pt 0pt 0pt 17.85pt; text-align:justify; text-indent:-17.85pt"><span style="font-family:'Times New Roman'; font-size:11pt">9.</span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">To review the multiple strain hypothesis.</span></p><p style="margin:0pt 0pt 0pt 17.85pt; text-align:justify; text-indent:-17.85pt"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">*The TSE guidance referred to above is the “Transmissible spongiform encephalopathy agents: safe working and the prevention of infection” first published in 2003 and available from: </span><a href="https://www.gov.uk/government/publications/guidance-from-the-acdp-tse-risk-management-subgroup-formerly-tse-working-group"><span style="color:#0000ff; font-family:'Times New Roman'; font-size:11pt; text-decoration:underline">https://www.gov.uk/government/publications/guidance-from-the-acdp-tse-risk-management-subgroup-formerly-tse-working-group</span></a><span style="color:#0000ff; font-family:'Times New Roman'; font-size:11pt; text-decoration:underline"> </span><span style="font-family:'Times New Roman'; font-size:11pt">(it also forms Appendix C of this evidence submission)</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><br style="page-break-before:always; clear:both" /></p><p style="margin:0pt 0pt 6pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Appendix E - CJD IP Organs and Tissue Position Statement</span></p><p style="margin:0pt 0pt 6pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold; text-decoration:underline">CJD Incidents Panel: Organ and Tissue Position Statement – September 2012 </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">[NB The CJD Incidents Panel was dissolved in March 2013]</span></p><p style="margin:0pt 0pt 6pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><p style="margin:0pt 0pt 6pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Introduction</span></p><p style="margin:0pt 0pt 6pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">The CJD Incidents panel developed an organs and tissues statement to capture decisions and discussions arising from the advice considered and given in relation to incidents over a number of years.  The following text was not published but provided an outline from which the Panel and the secretariat could provide consistent advice on any further incidents concerning organs and tissues.  It is intended that this position statement will be reviewed periodically or as required.</span></p><p style="font-size:11pt; line-height:115%; margin:6pt 0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><ol type="1" style="margin:0pt; padding-left:0pt"><li style="color:#111111; font-family:'Times New Roman'; font-size:11pt; font-weight:bold; line-height:115%; margin:6pt 0pt 6pt 13.25pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="color:#111111; font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Use of donated organs and tissues</span></li></ol><p style="font-size:11pt; line-height:115%; margin:10pt 0pt 6pt 18pt; text-align:justify; text-indent:-18pt"><span style="color:#111111; font-family:'Times New Roman'; font-size:11pt">1.1</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0; </span><span style="color:#111111; font-family:'Times New Roman'; font-size:11pt">The Panel should not advise clinicians on the use of organs and tissues donated by people with, at risk of, or with a positive test for CJD or vCJD.  Members considered that Advisory Committee on Safety of Blood, Tissues and Organs (SaBTO) was best placed to give advice on these issues.</span></p><p style="font-size:11pt; line-height:115%; margin:10pt 0pt 6pt 18pt; text-align:justify; text-indent:-18pt"><span style="color:#111111; font-family:'Times New Roman'; font-size:11pt">1.2</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0; </span><span style="color:#111111; font-family:'Times New Roman'; font-size:11pt">This does not affect the Panel’s advice to ‘at risk’ patients, not to donate organs or tissues.</span></p><p style="font-size:11pt; line-height:115%; margin:6pt 0pt; text-align:justify"><span style="color:#111111; font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><ol start="2" type="1" style="margin:0pt; padding-left:0pt"><li style="color:#111111; font-family:'Times New Roman'; font-size:11pt; font-weight:bold; line-height:115%; margin:6pt 0pt 6pt 13.25pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="color:#111111; font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Donors who test positive for vCJD at post mortem</span></li></ol><p style="font-size:11pt; line-height:115%; margin:10pt 0pt 6pt 18pt; text-align:justify; text-indent:-18pt"><span style="color:#111111; font-family:'Times New Roman'; font-size:11pt">2.1</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0; </span><span style="color:#111111; font-family:'Times New Roman'; font-size:11pt">Incidents involving asymptomatic donors who test positive for vCJD at post mortem, should be managed in the same way as incidents involving donors with symtomatic vCJD.</span></p><p style="font-size:11pt; line-height:115%; margin:6pt 0pt; text-align:justify"><span style="color:#111111; font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><ol start="3" type="1" style="margin:0pt; padding-left:0pt"><li style="color:#111111; font-family:'Times New Roman'; font-size:11pt; font-weight:bold; line-height:115%; margin:6pt 0pt 6pt 13.25pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="color:#111111; font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Type of organs and tissues from donors with vCJD</span></li></ol><p style="font-size:11pt; line-height:115%; margin:10pt 0pt 6pt 18pt; text-align:justify; text-indent:-18pt"><span style="color:#111111; font-family:'Times New Roman'; font-size:11pt">3.1</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0; </span><span style="color:#111111; font-family:'Times New Roman'; font-size:11pt">There was insufficient evidence on tissue infectivity levels to distinguish between the risks posed by different organs and tissues donated by patients with vCJD. Incidents involving all types of tissues and organs from donors with vCJD, including processed and unprocessed bone, should be managed in the same way. </span></p><p style="font-size:11pt; line-height:115%; margin:6pt 0pt; text-align:justify"><span style="color:#111111; font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><ol start="4" type="1" style="margin:0pt; padding-left:0pt"><li style="color:#111111; font-family:'Times New Roman'; font-size:11pt; font-weight:bold; line-height:115%; margin:6pt 0pt 6pt 13.25pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="color:#111111; font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Management of recipients</span></li></ol><p style="font-size:11pt; line-height:115%; margin:10pt 0pt 6pt 18pt; text-align:justify; text-indent:-18pt"><span style="color:#111111; font-family:'Times New Roman'; font-size:11pt">4.1</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0; </span><span style="color:#111111; font-family:'Times New Roman'; font-size:11pt">Patients who receive any tissue or organ from donors with vCJD, or donors who test positive for vCJD at post mortem, should be considered ‘at risk’ of vCJD for public health purposes. </span></p><p style="font-size:11pt; line-height:115%; margin:10pt 0pt 6pt 18pt; text-align:justify; text-indent:-18pt"><span style="color:#111111; font-family:'Times New Roman'; font-size:11pt">4.2</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0; </span><span style="color:#111111; font-family:'Times New Roman'; font-size:11pt">Patients who receive Haematopoietic stem cells HSC or</span><span style="color:#111111; font-family:'Times New Roman'; font-size:11pt; font-weight:bold"> </span><span style="color:#111111; font-family:'Times New Roman'; font-size:11pt">posterior eye tissues from donors with CJD should be considered ‘at risk’ of CJD for public health purposes. </span></p><p style="font-size:11pt; line-height:115%; margin:10pt 0pt 6pt 18pt; text-align:justify; text-indent:-18pt"><span style="color:#111111; font-family:'Times New Roman'; font-size:11pt">4.3</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0; </span><span style="color:#111111; font-family:'Times New Roman'; font-size:11pt">No actions are required for patients who have received any organs or other tissues from donors with CJD.</span></p><p style="font-size:11pt; line-height:115%; margin:10pt 0pt 6pt 18pt; text-align:justify; text-indent:-18pt"><span style="color:#111111; font-family:'Times New Roman'; font-size:11pt">4.4</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0; </span><span style="color:#111111; font-family:'Times New Roman'; font-size:11pt">In general, no actions are required for patients who have received tissues or organs from asymptomatic donors ‘at risk’ of vCJD or CJD. The exceptions to this are discussed in the next section ‘Reverse Risks’.</span></p><p style="font-size:11pt; line-height:115%; margin:10pt 0pt 6pt 18pt; text-align:justify"><span style="color:#111111; font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="5" type="1" style="margin:0pt; padding-left:0pt"><li style="color:#111111; font-family:'Times New Roman'; font-size:11pt; font-weight:bold; line-height:115%; margin:6pt 0pt 6pt 13.25pt; padding-left:4.6pt; text-align:justify; text-indent:0pt"><span style="color:#111111; font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Reverse risks</span></li></ol><p style="font-size:11pt; line-height:115%; margin:10pt 0pt 6pt 18pt; text-align:justify; text-indent:-18pt"><span style="color:#111111; font-family:'Times New Roman'; font-size:11pt">5.1</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0; </span><span style="color:#111111; font-family:'Times New Roman'; font-size:11pt">Donors of tissues or organs to recipients, who later develop vCJD, should be assessed and managed as if they had donated blood components i.e. as ‘at risk’ for public health purposes.  </span></p><p style="font-size:11pt; line-height:115%; margin:10pt 0pt 6pt 18pt; text-align:justify; text-indent:-18pt"><span style="color:#111111; font-family:'Times New Roman'; font-size:11pt">5.2</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0; </span><span style="color:#111111; font-family:'Times New Roman'; font-size:11pt">Recipients of any other tissues/organs from those donors (who have given tissues/organs to a recipient who developed vCJD), should be assessed and managed as if they had received blood components i.e. as ‘at risk’ for public health purposes.</span></p><p style="font-size:11pt; line-height:115%; margin:10pt 0pt 6pt 18pt; text-align:justify; text-indent:-18pt"><span style="color:#111111; font-family:'Times New Roman'; font-size:11pt">5.3</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0; </span><span style="color:#111111; font-family:'Times New Roman'; font-size:11pt">Donors of posterior eye tissues</span><span style="color:#111111; font-family:'Times New Roman'; font-size:11pt; font-weight:bold"> </span><span style="color:#111111; font-family:'Times New Roman'; font-size:11pt">or HSC to recipients who later develop CJD, should also be assessed and managed as for vCJD implicated blood components i.e. as ‘at risk’ for public health purposes. No actions are required for donors of organs</span><span style="color:#111111; font-family:'Times New Roman'; font-size:11pt; font-weight:bold"> </span><span style="color:#111111; font-family:'Times New Roman'; font-size:11pt">or other tissues to recipients who later develop CJD.</span></p><p style="font-size:11pt; line-height:115%; margin:10pt 0pt 6pt 18pt; text-align:justify; text-indent:-18pt"><span style="color:#111111; font-family:'Times New Roman'; font-size:11pt">5.4</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0; </span><span style="color:#111111; font-family:'Times New Roman'; font-size:11pt">Recipients of posterior eye tissues or HSC from those donors (who have given posterior eye tissues</span><span style="color:#111111; font-family:'Times New Roman'; font-size:11pt; font-weight:bold"> </span><span style="color:#111111; font-family:'Times New Roman'; font-size:11pt">or HSC to a recipient who developed CJD) should be assessed and managed as for vCJD implicated blood components i.e. as ‘at risk’ for public health purposes. No actions are required for the recipients of organs and other tissues from these donors.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Table 1: Action for organ/tissue recipients: by donor status and organ/tissue type</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><table cellspacing="0" cellpadding="0" style="border-collapse:collapse; margin-left:0pt; width:496.15pt"><tr><td rowspan="2" style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:92.2pt"><p style="margin:0pt 0pt 12pt; text-align:justify"><span style="color:#111111; font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Tissue/organ type</span></p></td><td colspan="5" style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:403.95pt"><p style="margin:6pt 0pt; text-align:justify"><span style="color:#111111; font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Donor status</span></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:70.85pt"><p style="margin:0pt; text-align:justify"><span style="color:#111111; font-family:'Times New Roman'; font-size:11pt; font-weight:bold">vCJD case</span><span style="color:#111111; font-family:'Times New Roman'; font-size:7.33pt; font-weight:bold; vertical-align:super">1</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:63.8pt"><p style="margin:0pt; text-align:justify"><span style="color:#111111; font-family:'Times New Roman'; font-size:11pt; font-weight:bold">CJD case</span><span style="color:#111111; font-family:'Times New Roman'; font-size:7.33pt; font-weight:bold; vertical-align:super">2</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:92.15pt"><p style="margin:0pt; text-align:justify"><span style="color:#111111; font-family:'Times New Roman'; font-size:11pt; font-weight:bold">At risk of vCJD following donation to vCJD recipient</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:92.1pt"><p style="margin:0pt; text-align:justify"><span style="color:#111111; font-family:'Times New Roman'; font-size:11pt; font-weight:bold">At risk of CJD following donation to CJD recipient</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:85.05pt"><p style="margin:0pt; text-align:justify"><span style="color:#111111; font-family:'Times New Roman'; font-size:11pt; font-weight:bold">At risk of CJD/vCJD for other reasons</span><span style="color:#111111; font-family:'Times New Roman'; font-size:7.33pt; font-weight:bold; vertical-align:super">3</span></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:92.2pt"><p style="margin:0pt; text-align:justify"><span style="color:#111111; font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Haematopoietic stem cells</span></p><p style="margin:0pt; text-align:justify"><span style="color:#111111; font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Posterior eye tissues</span></p></td><td rowspan="2" style="border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:70.85pt"><p style="margin:0pt; text-align:justify"><span style="color:#111111; font-family:'Times New Roman'; font-size:11pt">At risk recipient</span><span style="color:#111111; font-family:'Times New Roman'; font-size:7.33pt; vertical-align:super">4</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:63.8pt"><p style="margin:0pt; text-align:justify"><span style="color:#111111; font-family:'Times New Roman'; font-size:11pt">At risk recipient</span><span style="color:#111111; font-family:'Times New Roman'; font-size:7.33pt; vertical-align:super">4</span></p></td><td rowspan="2" style="border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:92.15pt"><p style="margin:0pt; text-align:justify"><span style="color:#111111; font-family:'Times New Roman'; font-size:11pt">Assess ‘at risk’ status of recipient as for vCJD implicated blood components</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:92.1pt"><p style="margin:0pt; text-align:justify"><span style="color:#111111; font-family:'Times New Roman'; font-size:11pt">Assess ‘at risk’ status of recipient as for vCJD implicated blood components</span></p></td><td rowspan="3" style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:85.05pt"><p style="margin:0pt; text-align:justify"><span style="color:#111111; font-family:'Times New Roman'; font-size:11pt">NFA</span><span style="color:#111111; font-family:'Times New Roman'; font-size:7.33pt; vertical-align:super">5</span></p></td></tr><tr style="height:12.65pt"><td rowspan="2" style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:92.2pt"><p style="margin:0pt; text-align:justify"><span style="color:#111111; font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Organs and other tissues including anterior eye</span></p></td><td rowspan="2" style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:63.8pt"><p style="margin:0pt; text-align:justify"><span style="color:#111111; font-family:'Times New Roman'; font-size:11pt">NFA</span><span style="color:#111111; font-family:'Times New Roman'; font-size:7.33pt; vertical-align:super">5</span></p></td><td rowspan="2" style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:middle; width:92.1pt"><p style="margin:0pt; text-align:justify"><span style="color:#111111; font-family:'Times New Roman'; font-size:11pt">NFA</span><span style="color:#111111; font-family:'Times New Roman'; font-size:7.33pt; vertical-align:super">5</span></p></td></tr><tr><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:70.85pt"><p style="margin:0pt; text-align:justify"><span style="color:#111111; font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:92.15pt"><p style="margin:0pt; text-align:justify"><span style="color:#111111; font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p></td></tr><!--[if !supportMisalignedColumns]><tr style="height:0pt"><td style="width:92.2pt; border:none"></td><td style="width:70.85pt; border:none"></td><td style="width:63.8pt; border:none"></td><td style="width:92.15pt; border:none"></td><td style="width:92.1pt; border:none"></td><td style="width:85.05pt; border:none"></td></tr><![endif]--></table><p style="margin:0pt; text-align:justify"><span style="color:#111111; font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:7.33pt; vertical-align:super">1</span><span style="font-family:'Times New Roman'; font-size:11pt"> This includes donors who are recipients of vCJD-implicated blood components. These recipients are managed as ‘at risk and presumed infected’ with vCJD. This category also includes donors with reactive vCJD tests at post mortem. For donors with a ‘possible’ (or unclear) CJD diagnosis, recipient notification should await diagnostic confirmation.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:7.33pt; vertical-align:super">2</span><span style="font-family:'Times New Roman'; font-size:11pt">CJD includes sporadic CJD, inherited prion disease, and iatrogenic CJD (but not iatrogenic vCJD).</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:7.33pt; vertical-align:super">3</span><span style="font-family:'Times New Roman'; font-size:11pt"> The ACDP TSE Working Group has defined the ‘at risk’ categories for vCJD/CJD </span><a href="http://www.advisorybodies.doh.gov.uk/acdp/tseguidance/Index.htm"><span style="color:#0000ff; font-family:'Times New Roman'; font-size:11pt; text-decoration:underline">http://www.advisorybodies.doh.gov.uk/acdp/tseguidance/Index.htm</span></a></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:7.33pt; vertical-align:super">4</span><span style="font-family:'Times New Roman'; font-size:11pt">Inform living recipient of their increased risk of vCJD/CJD, and the need to follow public health advice.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:7.33pt; font-weight:bold; vertical-align:super">5 </span><span style="font-family:'Times New Roman'; font-size:11pt">No further action.</span><a name="_Toc372806967"></a></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Appendix F - HAIRS Terms of Reference and Membership </span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">The Human Animal Infections and Risk Surveillance Group (HAIRS) members 2013</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">PUBLIC HEALTH ENGLAND (PHE)</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Gastrointestinal, Emerging and Zoonotic Infections Department, Health Protection Services:</span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Dilys Morgan (Chair)</span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">Head of Department</span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Hilary Kirkbride</span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">          </span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">Consultant Epidemiologist</span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Amanda Walsh</span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">          </span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">Senior Scientist</span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Catherine O’Connor</span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">Scientist </span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Virus Reference Department, Microbiology Services:</span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">David Brown</span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">           </span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">Director and Consultant Medical Virologist</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Microbial Risk Assessment: Emergency Response Department, Health Protection Services:</span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Jolyon Medlock</span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">          </span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">Head of Medical Entomology</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">DEPARTMENT FOR ENVIRONMENT, FOOD AND RURAL AFFAIRS (DEFRA)</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Elizabeth Kelly</span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">Head, Zoonoses Policy </span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Stephen Wyllie</span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">          </span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">Head, Endemics and Zoonoses</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Andrew Frost</span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">Veterinary Advisor (AHVLA)</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Lesley Larkin</span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">Veterinary Advisor (AHVLA)</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">ANIMAL HEALTH AND VETERINARY LABORATORIES AGENCY (AHVLA)</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Charlotte Featherstone</span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">Project Leader for Non-Statutory Zoonoses</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Cameron Stewart</span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">Veterinary Officer and Specialist in Veterinary Public Health</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Linda Smith</span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">                   </span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">Regional Veterinary Investigation and Surveillance Lead</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Paul Duff</span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">Leader of Diseases of Wildlife Scheme </span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">FOOD STANDARDS AGENCY (FSA)</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Geraldine Hoad</span><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">Head, Food Production Branch</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Sophie Rollinson</span><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">Senior Scientific Officer, Food Production Branch</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">DEPARTMENT OF HEALTH (DH)</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Maree Barnett</span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">Head of Emerging Infections Policy </span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Ruth Parry</span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">Infectious Diseases Scientific Policy Manager, Emerging Infections &amp; Zoonoses</span><span style="font-family:'Times New Roman'; font-size:11pt">              </span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">HEALTH PROTECTION SCOTLAND (HPS)</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Dominic Mellor</span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">        </span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">Veterinary Consultant</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">THE SCOTTISH GOVERNMENT</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Sheila Voas</span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">        </span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">Chief Veterinary Officer </span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">PUBLIC HEALTH WALES (PH WALES)</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Robert Smith</span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">                  </span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">Clinical Scientist (Zoonoses)</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">THE WELSH GOVERNMENT</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Arjen Brouwer</span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">Veterinary Advisor, Office of the Chief Veterinary Officer</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">PUBLIC HEALTH AGENCY, NORTHERN IRELAND</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Michael Devine</span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">Consultant Health Protection</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">DEPARTMENT OF AGRICULTURE AND RURAL DEVELOPMENT (DARD), NORTHERN IRELAND</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Paddy McGuckian</span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">Veterinary Officer (Zoonoses), Chief Veterinary Officer Group</span></p><h1 style="margin:24pt 0pt 0pt; page-break-after:avoid; page-break-inside:avoid; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Human-Animal Infections and Risk Surveillance group </span></h1><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">The Joint human-animal infections and risk surveillance (HAIRS) group is a Public Health England (PHE), Defra, Animal Health and Veterinary Laboratories Agency, Department of Health horizon scanning group chaired by PHE’s Department of Gastrointestinal, Emerging and Zoonotic Infections (GEZI). Representatives from Public Health Wales, Welsh Assembly Government, Health Protection Scotland, Scottish Government, Public Health Agency Northern Ireland, Department of Agriculture and Rural Development</span><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt">Northern Ireland and the Food Standards Agency also attend. The group meets every month and acts as a forum to identify and discuss infections with potential for interspecies transfer (particularly zoonotic infections). </span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">If infections are thought to be of significance, they are included in the “</span><span style="font-family:'Times New Roman'; font-size:11pt">Infectious Disease Surveillance and Monitoring System for Animal and Human Health: Summary of notable events/incidents of public health significance” </span><span style="font-family:'Times New Roman'; font-size:11pt">which is produced monthly by the EIZ Section at HPA Colindale. This output is circulated to members of ACDP, Department of Health, to Directors and others working in related areas in PHE, Defra departments and is placed on the PHE legacy website and Defra intranet.</span></p><h4 style="margin:10pt 0pt 0pt; page-break-after:avoid; page-break-inside:avoid; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic; font-weight:bold; text-decoration:underline">Terms of Reference </span></h4><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">The group is responsible for England, Wales, Scotland and Northern Ireland. The terms of reference of this group are still evolving but are currently:</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">1. Hazard Identification</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt"> To identify and review zoonotic or potentially zoonotic/interspecies infectious incidents which may pose a change in risk to animal or human health, whether these are acute clusters or outbreaks or increasing trends in reports of known or new infections or syndromes.  If the incident discussed falls within the remit of another group, the HAIRS group will ensure that the relevant group is aware and considering the event. These incidents are identified using a variety of sources and can be within the UK or international. </span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">2. Risk Assessment</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt"> If an infectious incident or trend has been identified, then the group discusses whether there might be a risk of interspecies transfer, which could pose a threat to animal or human public health. There are various levels of assessment and actions as outlined in annex 1 and the flow diagram.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">If a member of the group considers an incident to be of high public health significance, then the HAIRS group will be convened as rapidly as possible to discuss the implications of the event and ensure all the relevant agencies are informed. Members of the HAIRS group will also act as focus through which concerns of these agencies/groups can be considered by the group.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Risk assessment </span><span style="font-family:'Times New Roman'; font-size:11pt">is done using the expertise within the group or their network contacts. This allows incidents brought to the attention of the group considered to be of low public health importance to be “signed off” by the group. </span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">3. Risk Management</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Depending on the outcome of the risk assessment process, the HAIRS group may act as risk managers or refer issues to other groups for risk management action. </span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">For issues assessed as low risk or where direct action is not warranted, the group may “sign off” or “risk manage” the incident, or continue to monitor the situation and reassess the risk at appropriate intervals.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">For incidents assessed as being of potential threat to public health the group will alert appropriate groups to the situation and the need for risk management action. Members of the group will act as points of contact for the agencies and departments responsible for risk management. The HAIRS group then will not directly act as risk managers but may contribute advice and expertise to the risk management process. </span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">4. Risk Communication</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">The group will contribute to the monthly “</span><span style="font-family:'Times New Roman'; font-size:11pt">Infectious Disease Surveillance and Monitoring System for Animal and Human Health: Summary of notable events/incidents of public health significance”</span><span style="font-family:'Times New Roman'; font-size:11pt"> and be responsible for informing other agencies after assessing the change in risk as outlined in the annex. The group will be responsible for writing up and communicating the conclusions and recommendations of any expert qualitative risk assessment process. This information will be communicated to ACDP and the UK Zoonoses and Animal Diseases and Infections Group (UKZADI), for example through circulation of the HAIRS group minutes. </span></p><p style="margin:0pt; text-align:justify"><br style="page-break-before:always; clear:both" /></p><p style="margin:5pt 0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Annex 1 </span></p><h5 style="font-weight:normal; margin:10pt 0pt 0pt; page-break-after:avoid; page-break-inside:avoid; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Risk Assessment Process by the Human Animal Infections and Risk Surveillance Group</span></h5><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Incidents* are raised by a member of the group, discussed and:</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:-18pt"><span style="font-family:'Times New Roman'; font-size:11pt">a)</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt">Considered to be of negligible potential risk to public health </span><span style="font-family:Wingdings; font-size:11pt"></span><span style="font-family:'Times New Roman'; font-size:11pt"> no action apart from being minuted.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:-18pt"><span style="font-family:'Times New Roman'; font-size:11pt">b)</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt">Considered to be of negligible or little potential risk for interspecies transfer, but included in the monthly output for interest or information. However, the group will continue to monitor the situation.</span></p><p style="margin:0pt 0pt 0pt 18pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:-18pt"><span style="font-family:'Times New Roman'; font-size:11pt">c)</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt">More information is needed in order to assess the incident. The group produces background information and briefing papers in order that a preliminary assessment can be undertaken. Other members of the zoonoses network or other contacts may be consulted at this stage. Where UK animal surveillance profiles are available these will be used. After reviewing this information, an incident can be assessed as negligible or low change in risk to public health on the basis of the current information. This decision would be recorded in the monthly output and the situation would continue to be monitored. </span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:-18pt"><span style="font-family:'Times New Roman'; font-size:11pt">d)</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt">If considered that there is the potential for zoonotic or interspecies transfer either immediately or after reviewing further information, the group will then establish whether there needs to be a formal qualitative risk assessment by an expert group. If a formal risk assessment is thought to be necessary, the group will convene this and be responsible for informing other bodies, agencies and individuals eg Department of Health, ACDP, UKZADI, Food Standards Agency, PHE Directors of Health Protection and Microbiology Services, Defra, Chief Medical Officer(s), Chief Veterinary Officer(s) etc.  The expert group will include relevant national and international experts in animal and human health and will use an agreed risk assessment algorithm which has been approved by UKZADI. If the group considers the incident to be of high public health significance, an expert group will be convened as soon as possible.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:-18pt"><span style="font-family:'Times New Roman'; font-size:11pt">e)</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt">The group will be responsible for writing up and communicating the conclusions and recommendations of the expert group.</span></p><p style="margin:5pt 0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:5pt 0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">* “incidents” include acute clusters or outbreaks or increasing trends in reports of known or new infections or syndromes</span></p><p style="margin:0pt; text-align:right"><span style="font-family:'Times New Roman'; font-size:12pt">&#xa0;</span></p><p style="margin:0pt"><span style="font-family:'Times New Roman'; font-size:12pt">&#xa0;</span></p></div></body></html>